MyoKardia, Inc.
(NASDAQ : MYOK)

( )
MYOK After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MYOKMyoKardia, Inc. -0.03%221.941.8%$514.80m
HZNPHorizon Therapeutics Plc -1.47%78.465.8%$153.59m
VRXValeant Pharmaceuticals International, Inc. 0.58%17.2114.1%$101.27m
CTLTCatalent, Inc. -1.28%91.222.1%$87.19m
JAZZJazz Pharmaceuticals Plc -1.50%147.722.4%$85.89m
BHCBausch Health Cos., Inc. 0.58%17.210.0%$68.44m
ICLRICON plc 0.06%204.004.3%$49.79m
SAGESAGE Therapeutics, Inc. 0.91%69.728.6%$43.52m
ZGNXZogenix, Inc. -1.08%20.187.5%$42.59m
ARGXargenx SE -2.12%264.170.0%$42.31m
UTHRUnited Therapeutics Corp. 1.28%116.4714.1%$40.06m
AMRNAmarin Corp. Plc -2.33%5.031.5%$38.86m
ENDPEndo International Plc 13.25%5.648.7%$37.14m
SAVACassava Sciences, Inc. -6.11%9.840.0%$36.67m
PRGOPerrigo Co. Plc -3.69%45.636.8%$33.22m

Company Profile

MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.